OTHER FINANCIAL INFORMATION (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Other Financial Information [Abstract] |
|
| Summary of Accounts Receivable, net |
The following table summarizes our Accounts receivable, net: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | Accounts receivable(1) | | $ | 5,895 | | | $ | 5,319 | | | Less: allowances for chargebacks | | 843 | | | 759 | | | Less: allowances for cash discounts and other | | 97 | | | 89 | | | Less: allowances for credit losses | | 41 | | | 52 | | | Accounts receivable, net | | $ | 4,913 | | | $ | 4,420 | |
_______________________________ (1) As of December 31, 2025, the majority of our Accounts receivable balance arises from product sales in the U.S. and Europe and approximately 60% relates to three wholesalers—Cardinal Health, Cencora and McKesson—and their specialty distributor affiliates.
|
| Summary of Inventories |
The following table summarizes our Inventories: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | | Raw materials | | $ | 1,414 | | | $ | 1,295 | | | Work in process | | 1,306 | | | 847 | | | Finished goods | | 1,647 | | | 1,447 | | | Total | | $ | 4,368 | | | $ | 3,589 | | | | | | | | Reported as: | | | | | | Inventories | | $ | 1,774 | | | $ | 1,710 | | Other long-term assets(1) | | 2,594 | | | 1,879 | | | Total | | $ | 4,368 | | | $ | 3,589 | | _______________________________ (1) As of December 31, 2025, this amount primarily consists of raw materials and work in process.
|
| Summary of Prepaid and Other Current Assets |
The following table summarizes the components of Prepaid and other current assets: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | | Prepaid taxes | | $ | 899 | | | $ | 480 | | | Equity securities | | 1,981 | | | 1,577 | | | Other | | 1,144 | | | 995 | | | Prepaid and other current assets | | $ | 4,024 | | | $ | 3,052 | |
|
| Summary of Property, Plant and Equipment |
The following table summarizes our Property, plant and equipment, net by asset type: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | | Land and land improvements | | $ | 561 | | | $ | 561 | | | Buildings and improvements (including leasehold improvements) | | 4,622 | | | 4,539 | | | Laboratory and manufacturing equipment | | 1,241 | | | 1,192 | | | Internal-use software | | 666 | | | 692 | | | Other | | 466 | | | 397 | | | Construction in progress | | 745 | | | 501 | | | Subtotal | | 8,302 | | | 7,884 | | | Less: accumulated depreciation | | 2,696 | | | 2,470 | | | Total | | $ | 5,606 | | | $ | 5,414 | |
The following table summarizes our Property, plant and equipment, net by geography: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | | U.S. | | $ | 4,975 | | | 4,787 | | International(1) | | 631 | | | 627 | | | Total | | $ | 5,606 | | | $ | 5,414 | | _______________________________(1) All individual international locations accounted for less than 10% of the total balances. The following table summarizes Depreciation expense: | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | (in millions) | | 2025 | | 2024 | | 2023 | | Depreciation expense | | $ | 370 | | | $ | 381 | | | $ | 354 | |
|
| Summary of Other Current Liabilities |
The following table summarizes the components of Other current liabilities: | | | | | | | | | | | | | | | | | December 31, | | (in millions) | | 2025 | | 2024 | | Compensation and employee benefits | | $ | 1,298 | | | $ | 1,228 | | | Income taxes payable | | 92 | | | 1,646 | | | Allowance for sales returns | | 321 | | | 321 | | | Other | | 2,243 | | | 2,269 | | | Other current liabilities | | $ | 3,953 | | | $ | 5,464 | |
|
| Summary of Accumulated OCI by Component |
The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax: | | | | | | | | | | | | | | | | | | | | | | | | | | | | (in millions) | | Foreign Currency Translation | | Available-for-Sale Debt Securities | | Cash Flow Hedges | | Total | | Balance as of December 31, 2022 | | $ | 2 | | | $ | (33) | | | $ | 33 | | | $ | 2 | | Net unrealized gain (loss), net of income tax benefit of $0, $0, and $(2), respectively | | $ | 60 | | | $ | 26 | | | $ | (12) | | | $ | 75 | | Loss (gain) reclassified to net income, net of income tax expense of $0, $0, and $7, respectively | | — | | | 2 | | | (51) | | | (49) | | | Other comprehensive income (loss), net | | 60 | | | 28 | | | (62) | | | 26 | | | Balance as of December 31, 2023 | | $ | 62 | | | $ | (5) | | | $ | (29) | | | $ | 28 | | Net unrealized (loss) gain, net of income tax expense of $0, $0, and $21, respectively | | $ | (26) | | | $ | — | | | $ | 149 | | | $ | 124 | | Loss (gain) reclassified to net income, net of income tax expense of $0, $0, and $3, respectively | | — | | | 5 | | | (24) | | | (19) | | | Other comprehensive (loss) income, net | | (26) | | | 5 | | | 125 | | | 104 | | | Balance as of December 31, 2024 | | $ | 36 | | | $ | — | | | $ | 96 | | | $ | 132 | | Net unrealized gain (loss), net of income tax expense (benefit) of $0, $3, and $(20), respectively | | $ | 38 | | | $ | 9 | | | $ | (143) | | | $ | (97) | | (Gain) loss reclassified to net income, net of income tax expense (benefit) of $0, $0, and $(1), respectively | | — | | | — | | | 5 | | | 4 | | | Other comprehensive income (loss), net | | 38 | | | 8 | | | (139) | | | (93) | | | Balance as of December 31, 2025 | | $ | 74 | | | $ | 8 | | | $ | (43) | | | $ | 39 | |
The following table summarizes the reclassifications out of Accumulated other comprehensive income and into Net income, including the affected line items from our Consolidated Statements of Operations: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | | | (in millions) | | 2025 | | 2024 | | 2023 | | Line Item Affected | | | | | | Net (loss) gain related to cash flow hedges | | $ | (5) | | | $ | 27 | | | $ | 58 | | | Product sales | | | | | | Net (gain) loss related to available-for-sale debt securities | | $ | (1) | | | $ | 5 | | | $ | 2 | | | Other (income) expense, net | | | | | | Income tax (benefit) expense | | $ | (1) | | | $ | 3 | | | $ | 7 | | | Income tax (benefit) expense | | | | |
|
| Summary of Restructuring Charges |
The following table summarizes the affected line items from our Consolidated Statements of Operations: | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | (in millions) | | 2025 | | 2024 | | 2023 | | Cost of goods sold | | $ | 4 | | | $ | — | | | $ | 479 | | | Research and development expenses | | 68 | | | 98 | | | 20 | | | Selling, general and administrative expenses | | 66 | | | 91 | | | 28 | | | Restructuring charges | | $ | 138 | | | $ | 188 | | | $ | 527 | |
|
| Summary of Other (Income) Expense, Net |
The following table summarizes the components of Other (income) expense, net: | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | (in millions) | | 2025 | | 2024 | | 2023 | | (Gain) loss from equity securities, net | | $ | (451) | | | $ | 274 | | | $ | 167 | | | Interest income | | (349) | | | (281) | | | (376) | | | Other, net | | 1 | | | 2 | | | 11 | | | Other (income) expense, net | | $ | (798) | | | $ | (6) | | | $ | (198) | |
|